<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02137538</url>
  </required_header>
  <id_info>
    <org_study_id>AI growth study</org_study_id>
    <nct_id>NCT02137538</nct_id>
  </id_info>
  <brief_title>Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole</brief_title>
  <official_title>Randomization to Letrozole vs. Anastrozole in Short Pubertal Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if there are differences in the final height or
      hormone profile of short pubertal boys placed on different forms of aromatase inhibitor now
      routinely used to increase stature: Anastrozole and Letrozole. It also should determine if
      there are differences in the side effect profiles of the two drugs to be used.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2009</start_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adult height</measure>
    <time_frame>10 years</time_frame>
    <description>Heights will be obtained at physical exam every 6 months during treatment and annually until final height.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone density</measure>
    <time_frame>2 years</time_frame>
    <description>Baseline and 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spine x-ray</measure>
    <time_frame>2 years</time_frame>
    <description>Baseline and 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone age</measure>
    <time_frame>3 years</time_frame>
    <description>Bone ages will be obtained at baseline and annually during therapy. to calculate interim predicted adult heights.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>testosterone</measure>
    <time_frame>0.5 to 4 years</time_frame>
    <description>At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of testosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dihydrotestosterone</measure>
    <time_frame>0.5 to 4 years</time_frame>
    <description>At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of dihydrotestosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>androstenedione</measure>
    <time_frame>0.5 to 4 years</time_frame>
    <description>At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of androstenedione</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estradiol</measure>
    <time_frame>0.5 to 4 years</time_frame>
    <description>At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of estradiol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>estrone</measure>
    <time_frame>0.5 to 4 years</time_frame>
    <description>At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of estrone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inhibin B</measure>
    <time_frame>0.5 to 4 years</time_frame>
    <description>At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of inhibin B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>luteinizing hormone</measure>
    <time_frame>0.5 to 4 years</time_frame>
    <description>At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of luteinizing hormone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>follicle stimulating hormone</measure>
    <time_frame>0.5 to 4 years</time_frame>
    <description>At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of follicle stimulating hormone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin-like growth factor 1</measure>
    <time_frame>0.5 to 4 years</time_frame>
    <description>At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of insulin-like growth factor 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin-like growth factor binding protein 3</measure>
    <time_frame>0.5 to 4 years</time_frame>
    <description>At baseline, every 6 months, and 1 year post-treatment, we will obtain serum levels of insulin-like growth factor binding protein 3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Short Stature</condition>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Letrozole 2.5 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anastrozole 1 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <arm_group_label>Letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <arm_group_label>Anastrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current height less than 5th percentile AND/OR

          -  Predicted adult height (based on bone age) more than 10 cm below target height (mid
             parental height)

          -  Evidence of puberty: physical signs and serum luteinizing hormone &gt; 0.3 IU/L and
             testosterone &gt; 15 ng/dl

        Exclusion Criteria:

          -  Bone age reading more than 14.0 years

          -  Follicle stimulating hormone &gt; 20 IU/L
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E Kirk Neely, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>E Kirk Neely, MD</last_name>
    <phone>650 723-5791</phone>
    <email>neely@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E Kirk Neely, MD</last_name>
      <phone>650-723-5791</phone>
    </contact>
    <investigator>
      <last_name>E Kirk Neely, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Neely EK, Kumar RB, Payne SL, Ranadive SA, Suchet DI. Letrozole vs anastrozole for height augmentation in short pubertal males: first year data. J Clin Endocrinol Metab. 2014 Nov;99(11):4086-93. doi: 10.1210/jc.2014-2432. Epub 2014 Aug 19.</citation>
    <PMID>25137428</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 5, 2014</study_first_submitted>
  <study_first_submitted_qc>May 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2014</study_first_posted>
  <last_update_submitted>November 17, 2014</last_update_submitted>
  <last_update_submitted_qc>November 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

